Andere Sprachen Verrica Pharmaceuticals Inc.

Aktien

A2JPEV

US92511W1080

VRCA

Markt geschlossen - Nasdaq Andere Börsenplätze 22:30:01 03.05.2024			% 5 Tage	% 1. Jan.
7,26 ^USD	+7,40 %		+5,68 %	-0,82 %

26.03.	Ycanth von Verrica Pharmaceuticals erhält den Status einer neuen chemischen Entität und wird im Orange Book gelistet	MT
26.03.	Verrica Pharmaceuticals gibt bekannt, dass YCANTH? den Status einer neuen chemischen Entität und die Aufnahme in das Orange Book der FDA erhalten hat	CI

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

Verrica Pharmaceuticals Announces Presentation at the 23rd Annual Needham Virtual Healthcare Conference	02.04.
Verrica Pharmaceuticals Announces that YCANTH Receives New Chemical Entity Status and Orange Book Listing from the FDA	27.03.
Verrica Pharmaceuticals' Ycanth Gets New Chemical Entity Status, Orange Book Listing	26.03.
Verrica Pharmaceuticals Announces that YCANTH™ Receives New Chemical Entity Status and Orange Book Listing from the FDA	26.03.
Verrica Pharmaceuticals Announces that YCANTH? Receives New Chemical Entity Status and Orange Book Listing from the FDA	26.03.
VERRICA PHARMACEUTICALS INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Verrica Pharmaceuticals Inc. - VRCA	09.03.
Verrica Pharmaceuticals Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	29.02.
Verrica Pharmaceuticals Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	29.02.
Earnings Flash (VRCA) VERRICA PHARMACEUTICALS Reports Q4 Revenue $2M, vs. Street Est of $950,000	29.02.
Verrica Pharmaceuticals Reports Fourth Quarter and Full-Year 2023 Financial Results	29.02.
Verrica Pharmaceuticals Announces Participation in the TD Cowen 44th Annual Healthcare Conference	27.02.
Verrica Pharmaceuticals to Provide a Corporate Update and Report Fourth Quarter and Full-Year 2023 Financial Results on February 29, 2024	22.02.
Verrica Pharmaceuticals to Provide a Corporate Update and Report Fourth Quarter and Full-Year 2023 Financial Results on February 29, 2024	22.02.
VERRICA PHARMACEUTICALS INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Verrica Pharmaceuticals Inc. - VRCA	14.02.
Verrica Pharmaceuticals Sues Dormer Labs for Promoting Unapproved Cantharidin Drugs in US	05.02.
Verrica Pharmaceuticals Files Lawsuit Against Canadian Drug Manufacturer for False Advertising and Unfair Competition	05.02.
Verrica Pharmaceuticals Files Lawsuit Against Canadian Drug Manufacturer for False Advertising and Unfair Competition	05.02.
Verrica Pharmaceuticals Receives Permanent J-Code for YCANTH from Centers for Medicare and Medicaid Services	30.01.
Verrica Pharmaceuticals Receives Permanent J-Code (J7354) for YCANTH™ from Centers for Medicare and Medicaid Services	29.01.
Verrica Pharmaceuticals Receives Permanent J-Code for YCANTH from Centers for Medicare and Medicaid Services	29.01.

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen Verrica Pharmaceuticals Inc.

Aktien

A2JPEV

US92511W1080

VRCA

Andere Sprachen

Filter